1. Home
  2. PUBM vs EOLS Comparison

PUBM vs EOLS Comparison

Compare PUBM & EOLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PubMatic Inc.

PUBM

PubMatic Inc.

HOLD

Current Price

$8.28

Market Cap

303.6M

Sector

Technology

ML Signal

HOLD

Logo Evolus Inc.

EOLS

Evolus Inc.

HOLD

Current Price

$4.20

Market Cap

304.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PUBM
EOLS
Founded
2006
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
303.6M
304.0M
IPO Year
2020
2018

Fundamental Metrics

Financial Performance
Metric
PUBM
EOLS
Price
$8.28
$4.20
Analyst Decision
Buy
Strong Buy
Analyst Count
9
6
Target Price
$18.44
$17.40
AVG Volume (30 Days)
791.0K
686.0K
Earning Date
05-29-2026
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
25.00
EPS
N/A
N/A
Revenue
$282,926,000.00
$266,274,000.00
Revenue This Year
$0.85
$13.57
Revenue Next Year
$5.90
$11.39
P/E Ratio
N/A
N/A
Revenue Growth
N/A
31.76
52 Week Low
$6.15
$4.09
52 Week High
$13.26
$14.60

Technical Indicators

Market Signals
Indicator
PUBM
EOLS
Relative Strength Index (RSI) 68.40 35.24
Support Level $7.97 $4.09
Resistance Level $9.11 $4.99
Average True Range (ATR) 0.40 0.19
MACD 0.28 0.05
Stochastic Oscillator 90.21 25.33

Price Performance

Historical Comparison
PUBM
EOLS

About PUBM PubMatic Inc.

PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.

About EOLS Evolus Inc.

Evolus Inc is a performance beauty company with a customer-centric approach to delivering breakthrough products in the self-pay aesthetic market. The company's first commercial product is Jeuveau, a proprietary 900 kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Its primary market is the cash-pay aesthetic market, which includes medical products purchased by physicians and other customers that are then sold to consumers or used in procedures for aesthetic indications. It generates product revenue from the sale of Jeuveau in the United States and Europe, and service revenue from distribution partners in Canada.

Share on Social Networks: